Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2010

View Archived Issues

CMX-001 is not nephrotoxic in patients with viral infections

Cationic peptide NP-339 is active against Candida species

EP-017796 is active against drug-resistant bacteria

NNC-126-0083 is well tolerated in adults and children with growth hormone deficiency

Phase I investigation of CombiHIVvac HIV vaccine begins

FDA grants type B meeting to Repros to discuss phase III protocols for Androxal

Circassia advances novel T-cell allergy vaccines

Phase II trial of IMA-901 shows benefit of cyclophosphamide pretreatment

Bayer Schering Pharma identifies new activators of soluble guanylate cyclase

Teva and Oncogenex begin second phase III custirsen trial in prostate cancer

Merck Serono claims new inhibitors of PI3K

New inhibitors of C-raf/B-raf identified by Novartis

Data monitoring committee recommends continuation of phase III ThermoDox trial

Aveo Pharmaceuticals regains worldwide rights to AV-299

Repligen completes enrollment in phase IIb RG-2417 trial

Roche claims new inhibitors of NS5B for HCV infections

Banyu and Merck & Co. discover new PKB inhibitors

A&G Pharma receives NCI grant for GP88-directed antibody for breast cancer

Dyax and CMIC partner in development and marketing of DX-88 for HAE in Japan

Valeant Pharma and Biovail complete merger

Keryx advances phase III program for hyperphosphatemia treatment Zerenex

Ablynx begins enrollment in phase II trial of ALX-0081 and ALX-0681 in TTP

Phase III trial of lixisenatide in combination with basal insulin meets primary endpoint

PolyMedix receives phase II NIH grant to develop antimicrobial defensin mimetic

FDA grants fast track status to Emergent's AVP-21D9 anthrax program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...